MAP2K7 and melanoma: Available systemic treatments for patients with advanced melanoma include monoclonal antibodies, such as nivolumab that targets programmed cell death protein 1, and ipilimumab, which targets cytotoxic T-lymphocyte antigen-4, as well as oral small-molecule drugs that inhibit BRAF or MEK proteins [3].